10:00 am Chair’s Opening Remarks

Looking at Novel Targets & the Clinical Development for Solid Tumors

10:00 am Identification of Novel pHLA Targets for Solid Tumor Targeting with ADCs

Synopsis

  • Discuss the advantages of intracellular targets (pHLAs) versus viral, neoantigens or conventional cell surface antigens
  • Uncover strategies to find the most prevalent and immunogenic pHLA targets in tumors from CPI responders
  • Review the selection of ADCs targeting pHLA targets to avoid off-tumor, on-target toxicities in normal tissues

10:30 am Development & Clinical Translation of ELU001, a Targeted Ultra- Small Topoisomerase 1 C’Dot Conjugate for the Treatment of Solid Tumors

  • Greg Adams Chief Scientific Officer, Elucida Oncology, Inc

Synopsis

  • ELU001 is an ultra-small, 6 nM exatecan conjugated C’Dot Drug Conjugate (CDC) that is targeted to Folate Receptor Alpha via folic acid moieties on its surface
  • Understanding how Folate Receptor Alpha is an ideal target for CDC therapy due to its over expression on a variety of tumors and its limited expression on healthy tissues
  • Due to their size and neutral properties C’Dot Drug Conjugates (CDCs) localize in and penetrate rapidly into solid tumors including difficult to access tumors in the brain and pancreas

11:00 am Virtual Speed Networking

Synopsis

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ADC Targets field and establish meaningful business relationships to pursue for the rest of the conference.

12:00 pm SOT102, A Novel CLDN18.2-Targeting Antibody-Drug Conjugate With Strong Therapeutic Potential in Solid Tumors

Synopsis

  • SOT102 is based on a novel proprietary CLDN18.2 specific monoclonal antibody, conjugated to PNU-159682
  • Evaluate how SOT102 demonstrated strong antitumor activity in mouse
  • PDX models of gastric, pancreatic and other solid tumors, including those with low target expression
  • Gain an update on a Phase 1/2 study in patients with gastric and pancreatic cancer that is planned to start in early 2022

12:30 pm Quantitative Proteomics Approaches for ADC Target Characterization

Synopsis

  • Discuss DIA-MS peptide level quantification for epitope and isoform precision
  • Explore how to quantify cell surface protein dynamics using pulsed SILAC labeling
  • Examine the profiling of protein drug interactions (PDIs) using IP-MS

1:00 pm Lunch & Networking

2:00 pm Target Identification at the Intersection of Indication & Payload

  • Regina Reilly Oncology Discovery, Biologics & Research Fellow, AbbVie

Synopsis

  • Highlight the multifactorial aspect of target identification
  • Discuss the significance of comprehensive understanding of antigen expression as function of stage of tumorigenesis
  • Illustrate the enhanced value of pairing payload mechanism and indication

2:30 pm Session Reserved for Eisai

  • Earl Albone Senior Director of Biochemistry & Bioanalytical Development, Eisai, Inc

3:00 pm Chair’s Closing Remarks